Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20501819 | 0.86 | MAPT (0.55) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL4114732 | 0.84 | ALDH1A1 (0.51) | GAAMAPTHTTL3MBTL1MEN1 | |
| SCHEMBL14527733 | 0.83 | ALDH1A1 (0.45) | RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL1426050 | 0.82 | MAPT (0.52) | RAB9AGAAMAPTPRKCZPTPN11 | |
| SCHEMBL18614346 | 0.82 | MAPT (0.54) | RAB9AMAPTHTTL3MBTL1MEN1 | |
| SCHEMBL16370488 | 0.81 | ALDH1A1 (0.59) | RAB9AGAAMAPTHTTL3MBTL1 | |
| SCHEMBL1425605 | 0.81 | MAPT (0.61) | RAB9AGAAMAPTPTPN11L3MBTL1 | |
| SCHEMBL27634362 | 0.80 | TDP1 (0.50) | RAB9AMEN1KMT2A | |
| SCHEMBL4101439 | 0.80 | PPARD (0.44) | RAB9AGAAMAPTHTTL3MBTL1 | |
| SCHEMBL4114734 | 0.79 | MAPT (0.55) | MAPTL3MBTL1MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060229295-A1 | Amide derivatives | ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229295-A1 | Amide derivatives | VAC14, HDAC8, ZC3HAV1 | RAB9A 741/4885GAA 2221/4885AR 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.